he slope of the relationship between ventilation and carbon dioxide production (V • E/V • CO2 slope) is obtained during symptom-limited cardiopulmonary exercise testing, by plotting ventilation (V • E) vs carbon dioxide production (V • CO2). The increase in the V • E/V • CO2 slope reflects reduced ventilatory efficiency of gas exchange, which is associated with increased physiological dead space, as well as a decrease in the partial arterial pressure of carbon dioxide (PaCO2) regulatory set point. 1,2 The V
he slope of the relationship between ventilation and carbon dioxide production (V • E/V • CO2 slope) is obtained during symptom-limited cardiopulmonary exercise testing, by plotting ventilation (V • E) vs carbon dioxide production (V • CO2). The increase in the V • E/V • CO2 slope reflects reduced ventilatory efficiency of gas exchange, which is associated with increased physiological dead space, as well as a decrease in the partial arterial pressure of carbon dioxide (PaCO2) regulatory set point. 1, 2 The V
• E/V • CO2 slope is probably the best indicator of decreased pulmonary blood flow and is elevated in most patients with congestive heart failure (CHF). 3, 4 Besides the classical risk factors such as left ventricular ejection fraction (LVEF), New York Heart Association (NYHA) class IV symptoms and neurohormonal markers, peak oxygen consumption (V • O2) was found to predict survival in patients with CHF. 5, 6 Recently, the V
• E/V • CO2 slope was shown to be a better prognostic indicator than peak V
• O2, [7] [8] [9] suggesting that improvement in the slope could be used as an indicator of prolonged survival of patients with CHF.
Large clinical trials have established that -blockers improve left ventricular function and the survival of patients with CHF. [10] [11] [12] [13] Several studies have compared metoprolol with carvedilol for treating patients with mild to moderate CHF, [14] [15] [16] [17] and some have shown that carvedilol is more efficacious than metoprolol in improving LVEF and hemodynamic parameters. 15, 17 The recently published large-scale Carvedilol or Metoprolol European Trial (COMET) demonstrated that carvedilol reduces total mortality to a greater extent than metoprolol. 18 However, the relationship between the institution of -blocker therapy and the V
• E/V • CO2 slope in patients with CHF isstill unknown.
Thus, the purposes of this study were (1) to investigate whether administration of -blockers can improve the V
• E/V • CO2 slope, and (2) to compare the influence of 2 -blockers, carvedilol and metoprolol, on the V
• E/V • CO2 slope in patients with CHF.
Methods

Study Population
A total of 58 patients initially participated, but 1 patient was withdrawn because of sudden death. Therefore, a total of 57 patients with NYHA II-III CHF were examined. The etiology was dilated cardiomyopathy, ischemic, and valvular Key Words: Beta-blockers; Exercise; Heart failure; Ventilatory efficiency T heart diseases. Each patient had an LVEF <40% by radionuclide or contrast left ventriculography and were treated with conventional medical treatment including digitalis glycosides, diuretics, and angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers. They had been clinically stable under these medications for more than 3 months. Patients with a heart rate (HR) <50 beats/min, systolic blood pressure (BP) <90 mmHg, significant bradyarrhythmia, atrioventricular block, serum creatinine concentration >3.0 mg/dl, or presence of stenotic valvular heart disease, alcohol abuse, active myocarditis, or hypertrophic obstructive cardiomyopathy were excluded. Because most of this study had been conducted before the release of the Ethical Guidelines of Clinical Research (July 30, 2003) , the protocol had not been approved by the ethical committee. However, it conformed to the Ethical Guidelines of Clinical Research of the Ministry of Health, Labor and Welfare of Japan. Informed consent was given by all participants.
Study Protocol
Patients were randomized by lot into 2 groups to take either metoprolol tartrate or carvedilol, which were added to the usual treatment for CHF. Metoprolol and carvedilol were started at 5 mg/day and 2.5 mg/day, respectively, and the doses were gradually increased over 16 weeks until the target dose (80 mg/day and 20 mg/day, respectively) was attained, if tolerated (These are the accepted maximal doses of -blockers for Japanese patients with CHF. 19, 20 ) . If sideeffects developed, the increment in the dose was slowed or the dose was lowered or temporarily discontinued. Before and after 16 weeks of administration of -blocker, NYHA functional class, HR, and BP were determined, and ultrasound echocardiography and radionuclide ventriculography were performed.
The patients underwent a symptom-limited cardiopulmonary exercise test on an electronically braked computerized bicycle ergometer (Aerobic Exercise Ergometer, Nihon Kohden Corporation, Tokyo, Japan) with respiratory gas exchange measurement at baseline and after 16 weeks of treatment with -blockers. The protocol consisted of 2 min of pedaling without load, followed by 15 W/min incremental exercise to the point of exhaustion. Dyspnea or fatigue was the required endpoint for termination of exercise. The 12-lead electrocardiogram, HR, and BP were obtained at rest and at each minute during exertion (Q-STRESS, Nihon Kohden Corporation). V
• E, V • O2, V • CO2 and other exercise variables were computer-calculated. The V
• E/V • CO2 slope was determined as the linear regression slope of V
• E and V
• CO2 from the start of exercise until the RC point (the time at which ventilation is stimulated by CO2 output and endtidal CO2 tension begins to decrease). Peak V • O2 was defined as the average oxygen consumption during the final 20 s of maximal exercise. The anaerobic threshold (V • O2AT) was determined using the V-slope method. 21 We divided the study population into 2 groups according to baseline values of the plasma brain natriuretic peptide (BNP) concentration or LVEF as a post-hoc analysis. The median BNP concentration, 63 pg/ml, and median LVEF, 29%, were chosen as cutoff points to divide the study population into 2 groups.
Statistical Analysis
All data are expressed as mean ± SD unless otherwise indicated. Comparisons of baseline patient characteristics between 2 groups were made by Fisher's exact test or Student's unpaired t-test. Comparison of each parameter before and after the introduction of -blockers was performed using Student's paired t-test. Comparison of changes in each parameter between the 2 groups was made by a repeated measure analysis of variance. Statistical significance was defined as a p-value <0.05.
Results
Patients' Characteristics
There were 29 patients who received metoprolol and 28 who received carvedilol. Table 1 summarizes the baseline characteristics of the study groups. There were no differences in age, sex, NYHA functional class, etiology of heart failure, duration of illness, left ventricular end-diastolic dimension (LVEDD) on echocardiography, LVEF, or plasma BNP concentration. There was no difference between the 2 groups in usage of concomitant medication.
Cardiac Function and Cardiopulmonary Exercise Testing
LVEDD significantly decreased in the metoprolol group only, but LVEF significantly increased in both groups 16 weeks after the start of therapy (Fig 1) . The plasma BNP concentration did not significantly change after treatment in either group.
The HR at rest decreased significantly after treatment in both the metoprolol and carvedilol groups ( Table 2) . During exercise, HR decreased with both -blockers after 16 weeks from the start of therapy. There was no change in maximal workload, peak V
• O2, or the ratio of the change in oxygen uptake to work rate from baseline to 16 weeks after the start of therapy in either group.
Changes in Exercise Ventilatory Efficiency Based on Baseline Cardiac Function
In the overall patient group, the V • E/V • CO2 slope had not significantly changed after 16 weeks of therapy (32.3±0.7 at baseline vs 32.2±0.7 at 16 weeks).
Next we investigated the changes in the V • E/V • CO2 slope based on the baseline plasma BNP concentration or LVEF. In patients with a baseline BNP concentration >63 pg/ml, the V • E/V • CO2 slope had significantly improved 16 weeks after the start of therapy (Fig2). In contrast, in patients with a baseline BNP concentration <63pg/ml, the slope had significantly deteriorated from the start of therapy. Furthermore, in patients with a baseline LVEF <29%, the V
• E/V • CO2 slope had significantly improved at 16 weeks after the start of therapy (Fig 3) , but in patients with a baseline LVEF >29%, the slope had significantly deteriorated from the start of therapy.
Changes in Exercise Ventilatory Efficiency With -Blockers
In the overall patient group, the V • E/V • CO2 slope did not significantly change after treatment with either metoprolol or carvedilol, and the improvement effect on the V
• E/V • CO2 slope did not differ significantly between the metoprolol and carvedilol groups (Fig 4) . In patients with a baseline BNP concentration >63 pg/ml, the V
• E/V • CO2 slope significantly improved in the carvedilol group (p<0.01), but not in the metoprolol group. Furthermore, in patients with a baseline BNP concentration >63pg/ml, the improvement effect on the V
• E/V • CO2 slope with carvedilol was significantly greater than that with metoprolol (p<0.05). There were no significant differences between the 2 groups in their baseline characteristics (BNP >63 pg/ml metoprolol group vs BNP >63 pg/ml carvedilol group) ( Table 3 ). In patients with a baseline BNP <63 pg/ml, the V • E/V • CO2 slope did not change in either treatment group (Table 4) . According to the baseline LVEF, in patients with a baseline LVEF >29%, the V • E/V • CO2 slope significantly deteriorated in the metoprolol group (p<0.05). In patients with a baseline LVEF <29%, although the V • E/V • CO2 slope did not significantly change after either treatment, the changes in the slope of the carvedilol group tended to be greater than those in the metoprolol group. There were no significant differences between the 2 groups in the baseline characteristics (LVEF <29% metoprolol group vs LVEF <29% carvedilol group).
Discussion
The present study demonstrated that (1) slope significantly improved in patients with a higher baseline BNP concentration or a lower baseline LVEF, and (3) the changes in V • E/V • CO2 slope with carvedilol were significantly greater than those with metoprolol in patients with a higher baseline BNP concentration.
Measurement of the V • E/V • CO2 slope plays an important role in the treatment of patients with CHF, because it has been shown that an abnormally high slope predicts an increased risk of death among these patients, to an even greater degree than peak V
• O2. [7] [8] [9] Earlier studies have demonstrated that patients with a V
• E/V • CO2 slope of more than 34 have significantly higher 1-year cardiac-related mortality than other patients, 22 and that patients with a V
• E/V • CO2 slope of more than 35 have a similarly high mortality as those with a peak V
• O2 <10 ml·kg -1 ·min -1 . 23 A combination of V • O2AT <11 ml·kg -1 ·min -1 and V
• E/V • CO2 slope >34 better identifies patients at high risk for early death from CHF and is considered a better parameter for prioritizing patients for heart transplantation. 24 These findings suggest that an improvement in the V
• E/V • CO2 slope reflects prolongation of survival of patients with CHF.
There are a few studies that have documented the changes in V
• E/V • CO2 slope after -blocker therapy in patients with CHF. Recently, Agostoni et al demonstrated that the V
• E/ V
• CO2 slope in heart failure patients decreases after chronic administration of carvedilol. 25 In our study, the V • E/V • CO2 slope did not significantly decrease after administration of either carvedilol or metoprolol. Importantly, however, our results demonstrated that an improvement in the V
• E/V • CO2 slope occurred after administration of -blockers in patients with a higher baseline BNP concentration or a lower baseline LVEF. A higher plasma BNP concentration or a lower LVEF reflects poorer cardiac function, because plasma BNP is constitutively secreted by the ventricular myocardium and therefore reflects ventricular overloading. 26 Thus our results imply that the V
• E/V • CO2 slope improved only in patients with poorer baseline cardiac function. The patient population in the study done by Agostoni et al had a higher percentage classified as NYHA functional class III (9 patients: 60% vs 6 patients (40%) in class II), 25 whereas in the present study more patients were classified as NYHA functional class II (43 patients: 75% vs III [14 patients]: 25%). The fact that Agostoni et al's study included patients with poorer cardiac function than ours may have contributed to them finding a correlation between V
• E/V • CO2 slope decrease and carvedilol administration. Considering that the V • E/V • CO2 slope is a strong prognostic indicator, our results are consistent with those in a previous report from the Australia-New Zealand Heart Failure Group, which stated that in patients with CHF carvedilol prolonged life expectancy to a greater extent in patients with a higher baseline BNP concentration than in those with a lower baseline BNP concentration. 27 As Wasserman et al stated, an increase in the V • E/V • CO2 slope reflects reduced ventilatory efficiency of gas exchange, which is associated with an increased ratio of physiological dead space volume to tidal volume (VD/VT), as well as with a decrease in the PaCO2 regulatory set point. 1, 2, 28 First, let us consider the possibility that amelioration of the V
• E/V • CO2 slope is attributable to decreased VD/VT. The increment in cardiac output because of improved cardiac function with -blockers increases pulmonary flow, resulting in improved ventilation/perfusion mismatch and decreased VD/VT, and therefore, a decrease in the V
• E/V • CO2 slope. Thus, the poorer the original cardiac function, the greater the improvement in cardiac function and resulting VD/VT and ventilation/perfusion mismatch, which explains why patients with poorer cardiac function show greater improvement in the V
• E/V • CO2 slope. However, in the present study, there were no significant differences between the effect on amelioration of LVEF by carvedilol and that by metoprolol in patients with baseline poorer cardiac function, although the V • E/V • CO2 slope improved only in those patients who were treated with carvedilol. These findings raise the possibility that there is another factor affecting the V
• E/V • CO2 slope, other than improvement of VD/VT and ventilation/perfusion mismatch because of increment of LVEF.
Although carvedilol has been shown to improve the V • E/ V
• CO2 slope in heart failure patients, 25 there has not been a study comparing the effects between carvedilol and metoprolol on the V • E/V • CO2 slope. The present study demonstrated that in patients with a higher baseline BNP concentration the V
• E/V • CO2 slope significantly improved in those treated by carvedilol, but not in those treated by metoprolol, and the changes in the V
• E/V • CO2 slope with carvedilol were significantly greater than those with metoprolol. These findings suggest that carvedilol is more effective than metoprolol in improving the V
• E/V • CO2 slope in patients with advanced CHF. There are some differences in the pharmacologic properties of metoprolol and carvedilol. Metoprolol is a second-generation 1-selective blocking agent, and carvedilol is a third-generation 1-, 2-, and 1-blocker. 29 Carvedilol decreases the coronary sinus norepinephrine concentration and tends to suppress the number of myocardial -receptors, whereas metoprolol tends to increase the coronary sinus norepinephrine concentration. 14, 30 Because of these actions, the chronotropic response to exercise, which is an accurate measure of the cardiac response to sympathetic stimulation, 31, 32 has been shown to be attenuated more effectively by carvedilol than by metoprolol. 17 The greater improvement in clinical outcome in patients treated with carvedilol, which was reported recently by the COMET Study Group, 18,33 may be related to its ability to provide more comprehensive protection against the deleterious actions of the sympathetic nervous system on the heart during stress. Carvedilol decreased cardiac norepinephrine spillover, but such changes were not apparent in CHF patients treated with metoprolol. 34 On the other hand, the V • E/ V • CO2 slope is significantly increased by the actions of the sympathetic nervous system, 35 because the sympathetic nervous system controls CO2 sensitivity, a factor determining the V • E/V • CO2 slope, other than VD/VT, and the ventilatory response to exercise. 36, 37 These findings suggest that carvedilol may contribute to improvement of the V
• E/V • CO2 slope in patients with CHF not only through amelioration of ventilation -perfusion mismatching, but also through regulation of CO2 sensitivity caused by inhibition of sympathetic nervous system activity. Furthermore, intrinsic sympathetic activity is high in patients with advanced CHF with a high baseline plasma BNP concentration, 38 suggesting that sympathetic activity influences the V
• E/V • CO2 slope more in patients with a higher baseline BNP concentration than in other patients. Taken together, these findings may explain why in the present study carvedilol was more effective than metoprolol in improving the V
• E/V • CO2 slope in patients with a higher baseline BNP concentration.
Study Limitations
The main finding (ie, the significant improvement in the V
• E/V • CO2 slope with carvedilol in selected patients) obtained only by a post-hoc, retrospective analysis. The present patients were followed up for only 16 weeks, and thus the long-term effects of -blocker therapy on the V • E/V • CO2 slope are unknown. The severity of heart failure in the present patients was mild, as indicated by the high prevalence of NYHA II (75%) patients and a median BNP level of 63 pg/ml. A study of patients with more severe heart failure at baseline may be needed in the future.
